Chief Researcher at the Chumakov Institute, Academician of the Russian Academy of Sciences, Professor Alexei Egorov, in an interview with URA.RU, named the key feature of the new Russian vaccine against coronavirus.
According to him, the main difference between the Russian drug from the Chumakov Institute is that it is made not from individual coronavirus antigens, but from a whole inactivated virus. “Therefore, it gives a complete set of all antigens of this virus, and this gives a complete set of all antibodies,” the specialist said.
In his opinion, this feature of the drug will best protect the body from COVID-19. In addition, Yegorov added that the vaccine will be tentatively ready in February.
Earlier, Russian President Vladimir Putin spoke about the interest of dozens of countries in Russian vaccines against coronavirus. According to the head of state, “dozens of countries have already expressed a desire to establish cooperation in the supply and joint production of these drugs.” The Russian President also said that citizens of all states should have free access to vaccination.
To date, two vaccines against COVID-19 have been registered in the country. Sputnik V was the first to register. On October 14, President Vladimir Putin announced the registration of EpiVacKorona from the Vector Center.